Chronic Kidney Disease

>

Latest News

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

April 11th 2025

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose / image credit: ©New Africa/AdobeStock
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose

February 13th 2025

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease
Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

January 3rd 2025

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research
Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

November 7th 2024

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys: ©krishnacreations/stock.adobe.com
Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

October 21st 2024

© 2025 MJH Life Sciences

All rights reserved.